Board of Directors
James Williams – Non-Executive Chairman
Richard Lipscombe – Managing Director
Neville Gardiner – Non-Executive Director
Paul House – Non-Executive Director
Aaron Brinkworth – Non-Executive Director
Karen Logan – Company Secretary
Dr James Williams – Bsc (Hons), PhD (UWA), MBA (UWA), GAICD
James is an accomplished scientist, entrepreneur, manager, director and investor with experience covering all aspects of technology translation. Over the past 25 years he has been involved from concept to commercialisation, including as CEO, CTO, Director and Chair, of numerous public and private biotech companies which have resulted in five FDA approved drugs, devices and diagnostics. He conceived the technology behind iCeutica Inc (acquired in 2011) and co-discovered the lead therapy for ASX-listed Dimerix Limited (ASX:DXB), currently in Phase 3 trials for Chronic Kidney Disease.
James is currently CEO of the Health Translation Group, a not-for-profit company focusing on translation of medical research outcomes, a Director of the Perron Institute for Neurological and Translational Science and agriculture start-up Demagtech, and a member of the WA State Government’s Health and Medical Life Sciences Industry Advisory Group. He was previously co-founder and Investment Director of early-stage VC firm Yuuwa Capital LP, and appointed director on several portfolio companies, a Director of early-stage clinical trial facility Linear Clinical Research and a member of the Australian Federal Government’s Entrepreneurs’ Program Committee.
Dr Richard Lipscombe – PhD (London), MA (Oxford)
Richard, a co-founder of the Company, is a highly practised business manager and protein chemist expert in analysing biomolecules using proteomics techniques. He has an extensive expertise in chemistry, immunology, mass spectrometry, peptide synthesis, high performance computing and robotics.
Richard has international experience in both science and business gained over a 30-year period in Australia, USA and the UK, including work in hospital and academic laboratories and commercial organisations. He completed his chemistry degree (MA) at Oxford University, his PhD in immunology at London University and was a Post-Doctoral scientist (molecular immunology) in a large research institution in Australia (Telethon Kids Institute).
After managing the Protein Analysis Facility at the University of Western Australia, he co-founded Proteomics International Pty Ltd in 2001. Richard is well published in peer review journals, and holder of several patents.
Mr Neville Gardiner – BBus (Accounting and Business Law)
Mr Gardiner was recently a Partner of Deloitte in its M&A Advisory team. He is a seasoned finance professional with over 30 years’ experience advising Boards of public and private companies on mergers and acquisitions, project development, equity and debt capital markets, transaction structuring, capital allocation and complex commercial problem solving. Prior to Deloitte Mr Gardiner was Co-Founder and Managing Director of Torridon Partners, an independent corporate advisory firm. Torridon Partners was acquired by Deloitte in 2016.
He has held leadership positions at Macquarie Bank, Bank of America Merrill Lynch and Arthur Andersen, and has broad industry sector exposure including health-tech, fin-tech, mining and mining services, infrastructure, energy, and fabrication and construction.
Mr Paul House – GAICD, BCom (UWA)
Paul House is the current Chief Executive Officer of Imdex Limited, a leading global Mining-Tech company. He previously served eight years as the Managing Director of SGS India, where he was responsible for a workforce of approximately 4,500 personnel across 65 locations in India, including 38 laboratories. SGS is the world’s leading Testing, Inspection and Certification (TIC) company, and operates a network of offices and laboratories in more than 140 countries.
Mr House has previously held Chief Financial Officer and COO roles, and was Senior Manager for several years at a leading global management consultancy firm. Mr House has a track record for delivery of business performance targets, revenue growth, margin improvement, market share and productivity, across multiple services, markets and borders.
Mr Aaron Brinkworth – GAICD, BHIthSc (ECU)
Over a 22-year career at Gilead Sciences, Inc. (Nasdaq: GILD), he held senior commercial, patient access and strategic licensing roles. Mr Brinkworth has led Gilead’s Asia Pacific commercial and access operations where he was responsible for developing high performing sales, marketing, and distribution networks across the region. Mr Brinkworth currently serves as non-executive Director for Resonance Health Ltd (ASX: RHT).
Karen Logan – BCom, Grad Dip AppCorpGov, FCIS, FGIA, GAICD
Karen has extensive compliance, capital raising, merger and acquisition, IPO and backdoor listing experience in a diverse range of industries including technology, media, resources, health care and life science. She has assisted a substantial number of private start-up and established businesses transition to being publicly-listed companies for over 13 years.
Karen is presently the principal of a consulting firm and secretary of a number of ASX-listed companies, providing corporate and accounting services to those clients.
